Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application forLINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Announces-FDA-Filing-Acceptance-and-Priority-Review-of-Supplemental-New-Drug-Application-forLINZESS-linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspx

Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company
pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click here